Underscoring the high-stakes market for prostate cancer medicines, Bayer has filed a lawsuit accusing a rival, Johnson & Johnson, of launching a “false advertising campaign” that uses flawed data to wrongfully promote its drug as a more effective treatment.
At issue are claims J&J made in a Feb. 2 press release as well as in presentations on its website touting evidence that compared its Erleada prostate cancer drug with a Bayer medication called Nubeqa. Both drugs are so-called androgen receptor inhibitors that can prevent the growth of cancer cells and are frequently combined with other treatments.
It was only last June that Bayer won U.S. regulatory approval to market its drug in combination with androgen deprivation therapy, posing new competition for the J&J drug. This prompted J&J to react by promoting its medication as a superior choice in the press release and two website slide presentations aimed at physicians,
the lawsuit
stated.
Continue to STAT+ to read the full story…
— Source: STAT News (https://www.statnews.com/pharmalot/2026/02/23/bayer-jnj-prostate-cancer-false-advertising-lawsuit/)
